Literature DB >> 10516012

Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.

C Dupuy1, D Buzoni-Gatel, A Touzé, D Bout, P Coursaget.   

Abstract

Human papillomavirus type 16 (HPV-16) infects the genital tract and is closely associated with the development of cervical cancer. HPV-16 initiates infection at the genital mucosal surface; thus, mucosal immune responses are likely to contribute to defense against HPV-16 infection. However, little information is available regarding the induction of immune responses in the genital tract mucosa. In this study, we evaluated the potential of intranasally administered papillomavirus vaccines to elicit both systemic and vaginal immune responses. HPV-16 virus-like particles (VLPs) produced by self-assembly of L1 protein and the HPV-16 L1 gene cloned into a mammalian expression vector were used as vaccines. Intranasally administered VLPs induced serum immunoglobulin G (IgG) and vaginal IgA secretory antibodies. Very weak serum IgG and vaginal IgA responses were found after DNA immunization. Both splenic and vaginal lymphocytes could be activated by intranasal immunization with VLPs and the HPV-16 L1 gene. Activated CD4(+) Th1-like T cells were shown to synthesize gamma interferon, and activated CD8(+) T cells were demonstrated to be cytotoxic.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516012      PMCID: PMC112938     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Rotavirus virus-like particles administered mucosally induce protective immunity.

Authors:  C M O'Neal; S E Crawford; M K Estes; M E Conner
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Mucosal immunization with DNA encoding influenza hemagglutinin.

Authors:  E M Ban; F W van Ginkel; J W Simecka; H Kiyono; H L Robinson; J R McGhee
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

3.  Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site.

Authors:  B Wang; K Dang; M G Agadjanyan; V Srikantan; F Li; K E Ugen; J Boyer; M Merva; W V Williams; D B Weiner
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

4.  Genomic diversity and evolution of papillomaviruses in rhesus monkeys.

Authors:  S Y Chan; H U Bernard; M Ratterree; T A Birkebak; A J Faras; R S Ostrow
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina.

Authors:  C Bergquist; E L Johansson; T Lagergård; J Holmgren; A Rudin
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.

Authors:  D Nardelli-Haefliger; R B Roden; J Benyacoub; R Sahli; J P Kraehenbuhl; J T Schiller; P Lachat; A Potts; P De Grandi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

7.  Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast.

Authors:  R S Lowe; D R Brown; J T Bryan; J C Cook; H A George; K J Hofmann; W M Hurni; J G Joyce; E D Lehman; H Z Markus; M P Neeper; L D Schultz; A R Shaw; K U Jansen
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

8.  Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus.

Authors:  W S Gallichan; K L Rosenthal
Journal:  Vaccine       Date:  1995-11       Impact factor: 3.641

9.  Protection against papillomavirus with a polynucleotide vaccine.

Authors:  J J Donnelly; D Martinez; K U Jansen; R W Ellis; D L Montgomery; M A Liu
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

10.  Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques.

Authors:  B L Lohman; C J Miller; M B McChesney
Journal:  J Immunol       Date:  1995-12-15       Impact factor: 5.422

View more
  22 in total

Review 1.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse transcription-PCR.

Authors:  Véronique Revaz; Anne Debonneville; Martine Bobst; Denise Nardelli-Haefliger
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

4.  Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines.

Authors:  S K Eo; S Lee; S Chun; B T Rouse
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.

Authors:  Hee-Jung Lee; Jong Kwang Yoon; Yoonki Heo; Hansam Cho; Yeondong Cho; Yongdae Gwon; Kang Chang Kim; Jiwon Choi; Jae Sung Lee; Yu-Kyoung Oh; Young Bong Kim
Journal:  J Microbiol       Date:  2015-05-30       Impact factor: 3.422

6.  Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

Authors:  Peter Ohlschläger; Wolfram Osen; Kerstin Dell; Stefan Faath; Robert L Garcea; Ingrid Jochmus; Martin Müller; Michael Pawlita; Klaus Schäfer; Peter Sehr; Caroline Staib; Gerd Sutter; Lutz Gissmann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

8.  Oral immunogenicity of human papillomavirus-like particles expressed in potato.

Authors:  Heribert Warzecha; Hugh S Mason; Christopher Lane; Anders Tryggvesson; Edward Rybicki; Anna-Lise Williamson; John D Clements; Robert C Rose
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization.

Authors:  Waleed Mustafa; Paulo Cesar Maciag; Zhen-kun Pan; Jessica R Weaver; Yuhong Xiao; Stuart N Isaacs; Yvonne Paterson
Journal:  Viral Immunol       Date:  2009-06       Impact factor: 2.257

10.  Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.

Authors:  Hongtao Zhang; Raja Fayad; Xilin Wang; Daniel Quinn; Liang Qiao
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.